Dog Longevity Pills

Dog longevity drugs, date by date

Newest first. The filled marks are FDA steps.

Updated

Checked November 2, 2026 against Loyal's updates and the FDA. We look again every week.

  1. The FDA accepts LOY-003's effectiveness case, Loyal's third drug to reach that step. Loyal.

  2. Fortune reports the STAY study is about two and a half years in and built to detect a one-year difference in lifespan. Fortune.

  3. Loyal raises $100M for LOY-002's last regulatory work and to prepare its launch. Loyal.

  4. The FDA accepts LOY-002's safety package. Loyal now expects the last section, manufacturing, to be reviewed in 2027. Loyal.

  5. The STAY study closes enrollment at 1,300 senior dogs in 72 US vet clinics. Loyal.

  6. The FDA accepts LOY-002's effectiveness case. Loyal says it expects manufacturing and safety to be done by the end of 2025. Loyal.

  7. The TRIAD trial publishes its design: 580 dogs aged 7 and over, rapamycin or a placebo weekly for a year, with lifespan as the main measure. GeroScience (Coleman, Creevy and others).

  8. A $7M NIH grant keeps the Dog Aging Project's rapamycin trial (TRIAD) going, with 170 dogs enrolled at 20 sites. Texas A&M School of Veterinary Medicine.

  9. Boo, an 11-year-old whippet, becomes the first dog dosed in the STAY study of LOY-002. Loyal.

  10. The FDA accepts LOY-001's effectiveness case, the first time it has agreed a drug can be expected to extend a dog's life. Loyal.

  11. A six-month trial of a lower rapamycin dose in 17 dogs finds no difference in heart function and no serious side effects. Frontiers in Veterinary Science (Barnett and others).

  12. A University of Washington team publishes a 10-week rapamycin trial in 24 middle-aged pet dogs: the hearts of the dogs on the drug pumped better than those on a placebo. GeroScience (Urfer, Kaeberlein, Promislow and others).